Neurocrine Biosciences Inc. (NASDAQ:NBIX) Relative Strength Index (RSI) is 45.54, with weekly volatility at 3.32% and ATR at 3.15. The NBIX stock’s 52-week price range has touched low of $86.02 and a $136.26 high. Intraday shares traded counted 0.65 million, which was 44.13% higher than its 30-day average trading volume of 1.16M. Its shares traded lower over the last trading session, losing -1.56% on 05/19/21. The shares fell to a low of $91.96 before closing at $92.35. NBIX’s previous close was $93.81 while the outstanding shares total 94.20M. The firm has a beta of 0.77, a 12-month trailing P/E ratio of 22.53, and a growth ratio of 0.68.
Investors have identified the Biotechnology company Neurocrine Biosciences Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $8.49 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Neurocrine Biosciences Inc. (NBIX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 1.09 billion total, with 190.0 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 4.26 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on NBIX sounds very interesting.
Is the stock of NBIX attractive?
In related news, Chief Regulatory Officer, Lloyd-Smith Malcolm sold 1,700 shares of the company’s stock in a transaction that recorded on Feb 10. The sale was performed at an average price of 119.96, for a total value of 203,926. As the sale deal closes, the Chief Legal Officer, Lippoldt Darin now sold 36,194 shares of the company’s stock, valued at 4,204,831. Also, Chief Legal Officer, Lippoldt Darin sold 3,407 shares of the company’s stock in a deal that was recorded on Feb 08. The shares were price at an average price of 116.72 per share, with a total market value of 397,674. Following this completion of acquisition, the Chief Executive Officer, GORMAN KEVIN CHARLES now holds 10,466 shares of the company’s stock, valued at 1,221,864. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.30%.
16 out of 26 analysts covering the stock have rated it a Buy, while 7 have maintained a Hold recommendation on Neurocrine Biosciences Inc.. 0 analysts has assigned a Sell rating on the NBIX stock. The 12-month mean consensus price target for the company’s shares has been set at $128.00.